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translocation system to secrete the β-lactamase
BRO-2
Rachel Balder1, Teresa L Shaffer2 and Eric R Lafontaine1*Abstract
Background: Moraxella catarrhalis is a human-specific gram-negative bacterium readily isolated from the respiratory
tract of healthy individuals. The organism also causes significant health problems, including 15-20% of otitis media
cases in children and ~10% of respiratory infections in adults with chronic obstructive pulmonary disease. The lack
of an efficacious vaccine, the rapid emergence of antibiotic resistance in clinical isolates, and high carriage rates
reported in children are cause for concern. Virtually all Moraxella catarrhalis isolates are resistant to β-lactam
antibiotics, which are generally the first antibiotics prescribed to treat otitis media in children. The enzymes
responsible for this resistance, BRO-1 and BRO-2, are lipoproteins and the mechanism by which they are secreted to
the periplasm of M. catarrhalis cells has not been described.
Results: Comparative genomic analyses identified M. catarrhalis gene products resembling the TatA, TatB, and TatC
proteins of the well-characterized Twin Arginine Translocation (TAT) secretory apparatus. Mutations in the M.
catarrhalis tatA, tatB and tatC genes revealed that the proteins are necessary for optimal growth and resistance to
β-lactams. Site-directed mutagenesis was used to replace highly-conserved twin arginine residues in the predicted
signal sequence of M. catarrhalis strain O35E BRO-2, which abolished resistance to the β-lactam antibiotic
carbanecillin.
Conclusions: Moraxella catarrhalis possesses a TAT secretory apparatus, which plays a key role in growth of the
organism and is necessary for secretion of BRO-2 into the periplasm where the enzyme can protect the
peptidoglycan cell wall from the antimicrobial activity of β-lactam antibiotics.Background
Moraxella catarrhalis is a Gram-negative bacterium
primarily associated with otitis media in children and
respiratory infections in adults with compromised lung
function, particularly patients with Chronic Obstructive
Pulmonary Disease (COPD). The organism is also rea-
dily isolated from the upper respiratory tract of healthy
individuals and thus was considered a commensal bac-
terium until relatively recently. The rate of colonization
by M. catarrhalis varies depending on many factors such
as age, socioeconomic status, geography, and overall
health condition. It has been reported that ~2/3 of chil-
dren are colonized in their first year of life and 3-5% of* Correspondence: elafon10@uga.edu
1Department of Infectious Diseases, University of Georgia, Athens, GA 30602,
USA
Full list of author information is available at the end of the article
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reproduction in any medium, provided the oradults carry the organism asymptomatically. Following
initial colonization, there is a high rate of turnover, in-
dicating continual clearance and re-colonization by new
strains [1-27].
Moraxella catarrhalis possesses several virulence de-
terminants that enable it to persist in the human res-
piratory tract. A number of molecules in the outer
membrane have been shown to contribute to adherence,
allowing M. catarrhalis to bind and colonize the host
mucosa. These include LOS, UspA1, UspA2H, McaP,
OMPCD, Hag/MID, MhaB1, MhaB2, MchA1, MchA2,
and the type IV pilus [28-37]. In order to persist fol-
lowing colonization, M. catarrhalis possesses several
mechanisms to evade the host immune system including
resistance to complement. The best studied of these be-
ing UspA2 and UspA2H, which bind the C4-bindingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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OMPCD, OmpE, and LOS [31,37,42,43].
Moraxella catarrhalis is often refractory to antibiotic
treatment. Over 90% of isolates have been shown to pos-
sess a beta-lactamase, making them resistant to penicillin-
based antibiotics [44-51], which are typically prescribed
first to treat otitis media. The genes specifying this resis-
tance appear to be of Gram-positive origin [52,53], sug-
gesting that M. catarrhalis can readily acquire genes
conferring resistance to additional antibiotics via horizon-
tal transfer. Additionally, recent evidence has shown that
M. catarrhalis persists as a biofilm in vivo, giving it further
protection from antibiotic treatment and the host immune
response [54-58].
The bacterial twin-arginine translocation (TAT) sys-
tem mediates secretion of folded proteins across the
cytoplasmic membrane. The TAT apparatus typically
consists of three integral membrane proteins, namely
TatA, TatB, and TatC. TatA forms the pore through
which TAT substrates are secreted whereas TatB and
TatC are important for binding and directing the sub-
strates to the TatA pore. TatC acts as the gatekeeper for
the secretion apparatus and specifically recognizes TAT
substrates via a well-conserved signal sequence [59-62].
This signal sequence is similar to that of the gene-
ral secretory system in that it possesses N- (neutral),
H- (hydrophobic), and C- (charged) regions, but also
contains a TAT-recognition motif (S/T-R-R-x-F-L-K) ex-
hibiting nearly invariable twin arginines (RR) followed
by two uncharged residues [59-62]. Proteins secreted via
the TAT system are often, but not limited to, proteins
that bind cofactors in the cytoplasm prior to transport,
such as those involved in respiration and electron trans-
port, and proteins that bind catalytic metal ions [59-62].
The TAT system has also been shown to secrete several
factors important for bacterial pathogenesis including
iron acquisition, flagella synthesis, toxins, phospholi-
pases, and beta-lactamases [59,62-74]. In this study, we
identified genes encoding a TAT system in M. catar-
rhalis and mutated these genes in order to elucidate the
role of this translocase in the secretion of proteins that
may be important for pathogenesis.
Results and discussion
Identification of tatA, tatB and tatC genes in M. catarrhalis
Analysis of the patented genomic sequence of M.
catarrhalis strain ATCC43617 using NCBI’s tblastn ser-
vice (http://blast.ncbi.nlm.nih.gov/Blast.cgi) identified an
ORF (nucleotides 267,266 to 266,526 of GenBank acces-
sion number AX06766.1) that encodes a protein similar
to the tatC gene product of Pseudomonas stutzeri [75]
(expect value of 7e-56). TatC is the most highly-con-
served component of the TAT system among organismsknown (or predicted) to utilize this particular secretion
apparatus [59-62]. TatC is located in the cytoplasmic
membrane, typically contains 6 membrane-spanning
regions, and plays a key role in recognizing the twin-
arginine motif in the signal sequence of molecules se-
creted by the TAT system. TheM. catarrhalis ATCC43617
tatC-like ORF specifies a 27-kDa protein of 247 amino
acids, and analysis using the TMPred server (http://
www.ch.embnet.org/software/TMPRED_form.html) re-
vealed that it contains 6 potential membrane-spanning
domains (data not shown).
Sequence analysis upstream of the M. catarrhalis tatC
ortholog identified gene products similar to other con-
served components of the TAT system, TatA and TatB
(Figure 1). The ORF immediately upstream encodes a
178-residue protein with a molecular weight of 20-kDa
that resembles TatB of Providencia stuartii [76] (expect
value of 3e-8). Upstream of the M. catarrhalis tatB-like
gene, we identified an ORF specifying a 9-kDa protein of
77 aa that is most similar to TatA of Xanthomonas
oryzae [77] (expect value of 2e-5). TatA and TatB are
cytoplasmic proteins anchored to the cytoplasmic mem-
brane via hydrophobic N-termini. TatB forms a complex
with TatC often referred to as the twin-arginine motif
recognition module, while TatA oligomerizes and forms
a channel that is used to secrete TAT substrates [59-62].
Both M. catarrhalis ATCC43617 TatA (aa 4–21) and
TatB (aa 5–21) orthologs are predicted to contain hydro-
phobic membrane-spanning domains in their N-termini
using TMPred (data not shown). Together, these ob-
servations suggest that M. catarrhalis possesses a func-
tional TAT system.
To assess the presence and conservation of the tat
genes in other M. catarrhalis isolates, we amplified
and sequenced these genes from strains O35E, O12E,
McGHS1, V1171, and TTA37. The encoded gene prod-
ucts were then compared using ClustalW (http://www.
ebi.ac.uk/Tools/msa/clustalw2/). Of note, the annotated
genomic sequence of the M. catarrhalis isolate BBH18
has been published [78] and the predicted aa sequence
of the TatA (MCR_0127, GenBank accession number
ADG60399.1), TatB (MCR_0126, GenBank accession
number ADG60398.1) and TatC (MCR_0125, GenBank
accession number ADG60397.1) proteins were included
in our comparative analyses. Overall, the TatA and TatC
proteins are perfectly conserved. The TatB proteins div-
ide the strains into two groups where O35E, McGHS1,
TTA37, ATCC43617, and BBH18 are 100% identical to
each other, while O12E and V1171 both contain the
same aa substitution at residue 38 (S in lieu of G). We
also noted that in all isolates examined, the tatA and
tatB ORFs overlap by one nucleotide. A similar one-
nucleotide overlap is also observed for the tatB and tatC






Figure 1 Schematic representation of the M. catarrhalis tatABC locus. The relative position of tat-specific oligonucleotide primers (P1-P8)
used throughout the study is shown (see Methods section for details).
Balder et al. BMC Microbiology 2013, 13:140 Page 3 of 15
http://www.biomedcentral.com/1471-2180/13/140catarrhalis tatA, tatB, and tatC genes are transcriptio-
nally and translationally linked.
The M. catarrhalis tatA, tatB and tatC genes are necessary
for optimal growth
To study the functional properties of the Tat proteins in
M. catarrhalis, we constructed a panel of isogenic mu-
tant strains of isolate O35E in which the tatA, tatB and
tatC genes were disrupted with a kanamycin resistance
(kanR) marker. Each mutant was also complemented
with a plasmid encoding a wild-type (WT) copy of the
mutated tat gene and/or with a plasmid specifying the
entire tatABC locus. A growth defect was immediately
noted in the tat mutants as ~40-hr of growth at 37°C
was necessary for isolated colonies of appreciable size to
develop on agar plates, compared to ~20-hr for the par-
ent strain O35E. Hence, we compared the growth of the
tat mutants to that of the WT isolate O35E in liquid
medium under aerobic conditions. This was accom-
plished by measuring the optical density (OD) of cul-
tures over a 7-hr period. In some of these experiments,
we also plated aliquots of the cultures to enumerate col-
ony forming units (CFU) as a measure of bacterial
viability.
As shown in Figure 2A, the tatA, tatB and tatC mu-
tants carrying the control plasmid pWW115 had lower
OD readings than their progenitor strain O35E through-
out the entire course of the experiments. Significant dif-
ferences in the number of CFU were also observed
between mutants and WT strains (Figure 2B). Together,
these results demonstrate that mutations in the tatA,
tatB and tatC genes substantially reduce the growth rate
of M. catarrhalis cells. Complementation of the tatA
(Figure 3A) and tatB (Figure 3B) mutants with plasmids
encoding WT tatA (i.e. pRB.TatA) or tatB (i.e. pRB.TatB)
did not rescue the growth phenotype of these strains.
However, the construct pRB.TAT, which specifies the en-
tire tatABC locus, restored growth of the tatA and tatB
mutants to WT levels (Figure 3A and B). These results
support the hypothesis that the tatA, tatB and tatC
genes are transcriptionally and translationally linked due
to the one nucleotide overlaps between the tatA and
tatB, as well as the tatB and tatC ORFs. For the tatCmutant, O35E.TC, introduction of the plasmid pRB.
TatC, which encodes only the tatC gene, is sufficient to
restore growth to WT levels (Figure 3C). This finding is
consistent with the above observations since tatC is lo-
cated downstream of tatA and tatB (Figure 1), thus it is
unlikely that a mutation in tatC would affect the expres-
sion of either the tatA or tatB gene product. A tatC mu-
tation was also engineered in the M. catarrhalis isolate
O12E. The resulting strain, O12E.TC, exhibited a growth
defect comparable to that of the tatC mutant of strain
O35E, and this growth defect was rescued by the plas-
mid pRB.TatC (data not shown). These results demon-
strate that the importance of the TAT system to M.
catarrhalis growth is not a strain-specific occurrence.
Of note, all tat mutants carrying the control plasmid
pWW115 grew at rates comparable to the mutants con-
taining no plasmid (data not shown).
The tatA, tatB and tatC genes are necessary for the
secretion of β-lactamase by M. catarrhalis
TAT-deficient mutants of E. coli [79] and mycobacteria
[72-74,80] have been previously shown to be hypersen-
sitive to antibiotics, including β-lactams. Moreover, the
β-lactamases of M. smegmatis (BlaS) and M. tuberculosis
(BlaC) have been shown to possess a twin-arginine motif
in their signal sequences and to be secreted by a TAT
system [74]. More than 90% of M. catarrhalis isolates
are resistant to β-lactam antibiotics [44-51]. The genes
responsible for this resistance, bro-1 and bro-2, specify
lipoproteins of 33-kDa that are secreted into the peri-
plasm of M. catarrhalis where they associate with the
inner leaflet of the outer membrane [52,53]. Analysis of
the patented genomic sequence of M. catarrhalis strain
ATCC43617 with NCBI’s tblastn identified the bro-2
gene product (nucleotides 8,754 to 7,813 of GenBank ac-
cession number AX067438.1), which is predicted to en-
code a protein of 314 residues with a predicted MW of
35-kDa. The first 26 residues of the predicted protein
were found to specify characteristics of a signal sequence
(i.e. n-, h-, and c-region; see Figure 4A). Analysis with
the LipoP server (http://www.cbs.dtu.dk/services/LipoP/)
indicated a signal sequence cleavage site between resi-












Figure 2 Growth of the M. catarrhalis WT isolate O35E and tat mutant strains in liquid medium. Plate-grown bacteria were used to
inoculate sidearm flasks containing 20-mL of broth to an optical density (OD) of ~50 Klett units. The cultures were then incubated with shaking
at a temperature of 37°C for seven hours. The OD of each culture was determined every 60-min using a Klett Colorimeter. Results are expressed
as the mean OD ± standard error (Panel A). Aliquots (1-mL) were taken out of each culture after recording the OD, diluted, and spread onto agar
plates to determine the number of viable colony forming units (CFU). Results are expressed as the mean CFU ± standard error (Panel B). Growth
of the wild-type (WT) isolate O35E is compared to that of its tatA (O35E.TA), tatB (O35E.TB), and tatC (O35E.TC) isogenic mutant strains carrying
the control plasmid pWW115. Asterisks indicate a statistically significant difference in the growth rates of mutant strains compared to that of the
WT isolate O35E.
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due for lipid modification of this lipidated β-lactamase
[52]. Of significance, the putative signal sequence of
BRO-2 contains the highly-conserved twin-arginine rec-
ognition motif RRxFL (Figure 4), thus suggesting that
the gene product is secreted via a TAT system. Of note,
analysis of M. catarrhalis BRO-1 sequences available
through the NCBI database indicates that the molecules
also contain the twin-arginine recognition motif (data
not shown).
Based on these findings, we compared the ability of
our panel of WT and tat mutant strains to grow in the
presence of the β-lactam antibiotic carbenicillin. This
was accomplished by spotting equivalent numbers of
bacteria onto agar plates supplemented with the anti-
biotic. For comparison, bacteria were also spotted onto
agar plates without carbenicillin. These plates were in-
cubated for 48-hr at 37°C to accommodate the slower
growth rate of tat mutants. In contrast to WT M. ca-
tarrhalis O35E, which is resistant to carbenicillin, the
tatA (Figure 5A), tatB (Figure 5B), and tatC (Figure 5C)mutants were sensitive to the antibiotic. The introduc-
tion of plasmids containing a WT copy of tatA (i.e. pRB.
TatA, Figure 5A) and tatB (i.e. pRB.TatB, Figure 5B) did
not restore the ability of the tatA and tatB mutants to
grow in the presence of carbenicillin, respectively. Resist-
ance to the β-lactam was observed only when the tatA
and tatB mutants were complemented with the plasmid
specifying the entire tatABC locus (see pRB.TAT in
Figure 5A and B), which is consistent with the results of
the growth experiments presented in Figure 3. Introduc-
tion of the plasmid encoding only the WT copy of tatC
(i.e. pRB.TatC) in the strain O35E.TC was sufficient to
restore the growth of this tatC mutant on medium sup-
plemented with carbenicillin (Figure 5C). Of note, the
tatC mutant of strain O12E was tested in this manner
and the results were consistent with those obtained with
O35E.TC (data not shown). In order to provide an ap-
propriate control for these experiments, an isogenic
mutant strain of M. catarrhalis O35E was constructed
in which the bro-2 gene was disrupted with a kanR





















Figure 3 Growth of the M. catarrhalis WT isolate O35E and tat mutant strains in liquid medium. Plate-grown bacteria were used to
inoculate sidearm flasks containing 20-mL of broth to an OD of 50 Klett units. The cultures were then incubated with shaking at a temperature of
37°C for seven hours. The OD of each culture was determined every 60-min using a Klett Colorimeter. Panel A: Growth of O35E is compared to
that of its tatA isogenic mutant strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA (specifies a WT copy of tatA), and pRB.TAT
(harbors the entire tatABC locus). Panel B: Growth of O35E is compared to that of its tatB isogenic mutant strain, O35E.TB, carrying the plasmid
pWW115, pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: Growth of O35E is compared to that of its tatC isogenic mutant strain,
O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT copy of tatC). Growth of the bro-2 isogenic mutant strain O35E.Bro is also
shown. Results are expressed as the mean OD ± standard error. Asterisks indicate a statistically significant difference in the growth rates of mutant
strains compared to that of the WT isolate O35E.
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medium (Figure 3C). As expected, the bro-2 mutant
did not grow on agar plates containing carbenicillin
(Figure 5C).
The effect of tat mutations on the β-lactamase activity
of M. catarrhalis was quantitatively measured using the
chromogenic β-lactamase substrate nitrocefin. These as-
says were performed using suspensions of freshly plate-grown bacteria placed into the wells of a 48-well tissue
culture plate. A solution containing nitrocefin was added
to these suspensions and the change of color from yel-
low to red (indicative of cleavage of the β-lactam ring)
was monitored by measuring the absorbance of well
contents at a wavelength of 486 nm. Substantially less
β-lactamase activity was observed for the tatA, tatB
and tatC mutants compared to the WT strain O35E
NH2- -COOH
NH2- -COOH
A M. catarrhalis BRO-2
B Prototypical TAT signal sequence
n-region h-region c-region
n-region h-region c-region
Figure 4 Features of the M. catarrhalis BRO-2 signal sequence. The M. catarrhalis ATCC43617 bro-2 gene product was analyzed using the
SignalP 4.0 server. Panel A: The first 30 amino acid of BRO-2 are shown. Residues 1–26 specify characteristics of a prokaryotic signal sequence,
specifically neutral (n, highlighted in yellow), hydrophobic (h, highlighted in blue) and charged (c, highlighted in red) regions. The highly-
conserved twin-arginine recognition motif is bolded and underlined. Panel B: Features of a typical TAT signal sequence where x represents any
amino acid (adapted from [59]). The arrowheads indicate signal peptidase cleavage sites.
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tants with plasmids containing only the WT copies of
the inactivated genes did not restore β-lactamase ac-
tivity, as expected based on the results of the experi-
ments depicted in Figures 3 and 5. The plasmid pRB.
TAT, which specifies the entire tatABC locus, restored
the ability of the mutants O35E.TA (Figure 6A) and
O35E.TB (Figure 6B) to hydrolyze nitrocefin. The plas-
mid pRB.TatC was sufficient to rescue β-lactamase acti-
vity in the tatC mutant strain O35E.TC to near WT
levels (Figure 6C). The tatC mutant of strain O12E was
tested in this manner and the results were consistent
with those obtained with O35E.TC (data not shown).
The control strain, O35E.Bro, was impaired in its ability
to hydrolyze nitrocefin at levels comparable to those of
the tatA, tatB and tatC mutants (Figure 6A, B and C).
Taken together, these results suggest that the M. ca-
tarrhalis tatABC locus is necessary for secretion of the
β-lactamase BRO-2 into the periplasm where the en-
zyme can protect the peptidoglycan cell wall from the
antimicrobial activity of β-lactam antibiotics.
To conclusively demonstrate that M. catarrhalis BRO-
2 is secreted by the TAT system, we cloned the bro-2
gene of strain O35E in the plasmid pWW115 (pTS.Bro)
and used site-directed mutagenesis to replace the twin-
arginine (RR) residues in BRO-2’s predicted signal se-
quence (Figure 4A) with twin lysine (KK) residues (pTS.
BroKK). Similar conservative substitutions have been
engineered in TAT substrates of other bacteria to de-
monstrate the importance of the RR motif in TAT-
dependent secretion [74]. These plasmids were intro-
duced in the mutant O35E.Bro and the recombinant
strains were tested for their ability to hydrolyze nitro-
cefin. As shown in Figure 7A, expression of the mutated
BRO-2 from plasmid pTS.BroKK did not restore the
ability to hydrolyze nitrocefin. These results establish
that the M. catarrhalis β-lactamase BRO-2 is secreted
into the periplasm by the TAT system. Interestingly, themutation in the RR motif of BRO-2 also interfered with
secretion of the β-lactamase by recombinant Haemophi-
lus influenzae DB117 bacteria (Figure 7B).
Identification of other M. catarrhalis gene products
potentially secreted by the TAT system
To identify other M. catarrhalis molecules that may be
secreted via the TAT apparatus, the annotated genomic
sequences of strains ATCC43617 [81] and BBH18 [78]
were analyzed with prediction algorithms available
through the TatFind 1.4 [82] and TatP 1.0 [83] servers.
Although these servers are designed for the same purpose
(i.e. identify proteins secreted by the TAT system), the al-
gorithms used for each differ and as such proteins identi-
fied as TAT substrates do not overlap 100% between the
two prediction algorithms.
Six ORFs were predicted to be TAT substrates in strain
ATCC43617, only one of which was identified by both
algorithms (Figure 8). The TatP 1.0 server identified
MCORF 312 and MCORF 1197 as proteins potentially
secreted by the TAT system, but no twin-arginine motif
was found within the signal sequences of these gene
products. Conversely, the TatFind 1.4 server identified
MCORF 1917 as a TAT substrate and a twin-arginine
motif was observed between residues 18 and 23. Al-
though the encoded protein does not specify charac-
teristics of a prokaryotic signal sequence (i.e. n-, h-,
c-region), a potential lipoprotein signal sequence clea-
vage site was identified using the LipoP server. Inte-
restingly, the MCORF 1197 and MCORF 1199 gene
products resemble cytochrome c molecules involved in
the electron transport chain. Cytochromes have been
predicted, as well as demonstrated, to be TAT substrates
in several bacterial species [84-87]. MCORF 1917 ex-
hibits similarities to iron-dependent peroxidases, which
is consistent with the previously reported role of the
TAT system in the secretion of enzymes that bind metal





























Figure 5 Growth of the M. catarrhalis WT isolate O35E and tat mutant strains in the presence of the β-lactam antibiotic carbenicillin.
The ability of tat mutants to grow in the presence of carbenicillin (cab) was tested by spotting equivalent numbers of bacteria onto Todd-Hewitt
agar plates supplemented with the antibiotic (TH + cab). As control, bacteria were also spotted onto agar plates without carbenicillin (TH). These
plates were incubated for 48 hrs at 37°C to accommodate the slower growth rate of the tat mutants. Panel A: Growth of O35E is compared to
that of its tatA isogenic mutant strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA (specifies a WT copy of tatA), and pRB.TAT
(harbors the entire tatABC locus). Panel B: Growth of O35E is compared to that of its tatB isogenic mutant strain, O35E.TB, carrying the plasmid
pWW115, pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: Growth of O35E is compared to that of its tatC isogenic mutant strain,
O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT copy of tatC). Growth of the bro-2 isogenic mutant strain O35E.Bro is also
shown. The results are shown as a composite image representative of individual experiments that were performed in duplicate on at least 3
separate occasions.
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838 shows similarities to a family of C-terminal pro-
cessing peptidases and contains important functional
domains including a post-translational processing, ma-
turation and degradation region (PDZ-CTP), and a peri-
plasmic protease Prc domain described as important for
cell envelope biogenesis.
Six putative TAT substrates were identified in the
genome of M. catarrhalis strain BBH18, five of whichoverlapping those predicted in ATCC43617 (Figure 8).
Strain BBH18 specifies the unique TAT substrate
MCR_920, which is predicted to be a highly-conserved
phosphatase (Figure 8). The MCORF 1659 of strain
ATCC43617 encodes a gene product that is 96.8% iden-
tical to this putative phosphatase, but neither of the
TatFind 1.4 and TatP 1.0 servers identified the ORF as a
TAT substrate, likely due to significant amino acid di-











Figure 6 Quantitative measurement of the β-lactamase activity
produced by the M. catarrhalis WT isolate O35E and tat mutant
strains. The β-lactamase activity of strains was measured using the
chromogenic compound nitrocefin. Bacterial suspensions were
mixed with a 250 μg/mL nitrocefin solution and the absorbance at
486 nm (A486) was immediately measured and recorded as time “0”
(open bars). The A486 of the samples was measured again after a
30-min incubation at room temperature (black bars). Panel A: The
β-lactamase activity of O35E is compared to that of the tatA mutant
strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA
(specifies a WT copy of tatA), and pRB.TAT (harbors the entire tatABC
locus). Panel B: The β-lactamase activity of O35E is compared to
that of the tatB mutant, O35E.TB, carrying the plasmid pWW115,
pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: The
β-lactamase activity of O35E is compared to that of the tatC mutant,
O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT
copy of tatC). The strain O35E.Bro, which lacks expression of the
β-lactamase BRO-2, was used as a negative control in all experiments
in addition to the broth-only control. The results are expressed as the
mean A486 ± standard error. Asterisks indicate that the reduction in the
β-lactamase activity of mutants is statistically significant (P < 0.05) when
compared to the WT strain O35E.
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tidase (MCR_1063) that is 98.1% identical to the puta-
tive TAT substrate MCORF 838 of ATCC43617. Like
the MCORF 838 of ATCC43617, the BBH18 gene pro-
duct lacked a TAT motif in its signal sequence (data not
shown). Despite these similarities, the BBH18 MCR_1063
C-terminal processing peptidase was not identified as a
being potential TAT substrate by the TatFind 1.4 or TatP
1.0 algorithms.
Conclusions
This report is the first characterization of a secretory
apparatus for M. catarrhalis. Our data demonstrate that
the TAT system mediates secretion of β-lactamase and is
necessary for optimal growth of the bacterium. Moraxella
catarrhalis is a leading cause of otitis media worldwide
along with Streptococcus pneumoniae and non-typeable
Haemophilus influenzae (NTHi), and is often found in
mixed infections with these organisms [1-8,89]. In con-
trast to M. catarrhalis, most S. pneumoniae and NTHi
isolates are susceptible to β-lactam antibiotics [90]. In a
set of elegant studies, Schaar et al. demonstrated that
outer membrane vesicles produced by M. catarrhalis con-
tain β-lactamase and function as a long-distance delivery
system to confer antimicrobial resistance for β-lactamase
negative isolates of S. pneumoniae and NTHi [91]. This
constitutes a novel mechanism by which M. catarrhalis
promotes survival and infection by other pathogens in the
context of polymicrobial disease. Hence, a greater under-
standing of the TAT secretion system of M. catarrhalis is
a key area of future study as it may lead to the develop-
ment of innovative strategies to improve the efficacy of
existing antimicrobials used to treat bacterial infections









Figure 7 Quantitative measurement of the β-lactamase activity
of M. catarrhalis and recombinant H. influenzae strains.
β-lactamase activity was measured using the chromogenic
compound nitrocefin. Bacterial suspensions were mixed with a
250 μg/mL nitrocefin solution and the A486 was immediately
measured and recorded as time “0” (open bars). The A486 of the
samples was measured again after a 30-min incubation at room
temperature (black bars). Panel A: The β-lactamase activity of M.
catarrhalis O35E is compared to that of the bro-2 mutant, O35E.Bro,
carrying plasmids pWW115, pTS.Bro, and pTS.BroKK. Panel B: The
β-lactamase activity of H. influenzae DB117 carrying plasmids pWW115,
pTS.Bro, and pTS.BroKK is compared. Sterile broth was used as a
negative control in these experiments. The results are expressed as the
mean ± standard error A486. Asterisks indicate that the reduction in the
β-lactamase activity of strains lacking expression of BRO-2, or
expressing a mutated BRO-2 that contains two lysine residues in its
signal sequence instead of 2 arginines, is statistically significant
(P < 0.05) when compared to bacteria expressing a WT copy of the
bro-2 gene.
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catarrhalis could be used in concert with β-lactam an-
tibiotics as β-lactamase inhibitors. This hypothesis is
supported by the recent discovery that the compounds
N-phenyl maleimide and Bay 11–7782 specifically inter-
fere with TAT-dependent secretion of the Pseudomonas
aeruginosa phospholipase C PlcH [92].
Methods
Bacterial strains, plasmids, and growth conditions
Strains and plasmids are described in Table 1. M. catar-
rhalis was cultured using Todd-Hewitt (TH) medium
(BD Diagnostic Systems) supplemented with 20 μg/mL
kanamycin, 15 μg/mL spectinomycin, and/or 5 μg/mL car-
benicillin, where appropriate. Escherichia coli was grown
using Luria-Bertani (LB) medium (Fisher BioReagents)
supplemented with 15 μg/mL chloramphenicol and/or
50 μg/mL kanamycin, where indicated. Haemophilus in-
fluenzae was cultured using Brain Heart Infusion (BHI)
medium (BD Diagnostic Systems) supplemented with
50 mg/L hemin chloride (Sigma-Aldrich®) and 10 mg/L
NAD (Sigma-Aldrich®) (BHI +Heme +NAD). This medium
was further supplemented with 50 μg/mL spectinomycin
where appropriate. Electrocompetent M. catarrhalis and H.
influenzae cells were prepared as previously described [93].
All strains were cultured at 37°C in the presence of
7.5% CO2.
Recombinant DNA techniques
Standard molecular biology techniques were performed
as described elsewhere [97]. Moraxella catarrhalis
genomic DNA was obtained using the Easy-DNA™ kit
(Invitrogen™ Life Technologies™) per the manufacturer’s
instructions. Plasmid DNA was purified with the QIAprep
Spin Miniprep system (QIAGEN).
Polymerase chain reactions were performed using Taq
DNA Polymerase (Invitrogen™ Life Technologies™) un-
less otherwise specified. A 1,018-nt fragment containing
the tatC gene was amplified with primers P1 (5′- AAA
GCCAAGCCAACGGACTT-3′) and P2 (5′-ACCTCC
AAGAAACCCACGCTATCA-3′) using genomic DNA
from M. catarrhalis strain O12E (see Figure 1 for more
details regarding primers). This PCR product was cloned
into the vector pCC1 using the Copy Control™ PCR
Cloning Kit (Epicentre® Illumina®) per the manufacturer’s
instructions. This process yielded plasmid pRB.TatC.2,
which was sequenced to verify that mutations were not
introduced in the tatC gene during cloning. PCR prod-
ucts comprising tatA (886-nt in length), tatB (858-nt in
length) and the entire tatABC locus (2,083-nt in length)
were amplified with primers P3 (5′-AGGGCAACTG
GCAAATTACCAACC-3′) and P4 (5′-AAACATGCCA
TACCATCGCCCAAG-3′), P5 (5′-CAAAGACTTGGG
CAGTGCGGTAAA-3′) and P6 (5′-ATTCATTGGGCA
Figure 8 Comparison of the putative TAT substrates identified in the genomes of M. catarrhalis strains ATCC43617a and BBH18b.
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CAAAGAGCTTGA-3′) and P8 (5′-AGCTTGCCGAT
CCAAACAGCTTTC-3′), respectively, using genomic
DNA from M. catarrhalis strain O35E (see Figure 1 for
more details regarding primers). These amplicons were
cloned in the vector pCC1 as described above, produ-
cing plasmids pRB.TatA.5, pRB.TatB.1, and pRB.Tat.1.
These constructs were sequenced to verify that muta-
tions were not introduced in the tat genes during PCR.
To examine conservation of the TatABC gene products,
genomic DNA from M. catarrhalis strains O35E, O12E,
McGHS1, V1171, and TTA37 was used to amplify 2.1-kb
DNA fragments containing the entire tatABC locus with
primer P7 and P8. These amplicons were sequenced
in their entirety and the sequences were deposited in
GenBank under accession numbers HQ906880 (O35E),
HQ906881 (O12E), HQ906882 (McGHS1), HQ906883
(V1171), and HQ906884 (TTA37).
The bro-2 gene specifying the β-lactamase of M.
catarrhalis strain O35E was amplified with primers P9
(5′-TAATGATGCAACGCCGTCAT-3′) and P10 (5′-GC
TTGTTGGGTCATAAATTTCC-3′) using Platinum® Pfx
DNA Polymerase (Invitrogen™ Life Technologies™). This
994-nt PCR product was cloned into pCC1 as described
above, generating the construct pRN.Bro11. Upon se-
quencing, the bro-2 gene contained by pRN.Bro11 was
found to be free of mutation. The nucleotide sequence
of O35E bro-2 was deposited in GenBank under the ac-
cession number JF279451.Mutant construction
To create a tatC mutation in M. catarrhalis, the plasmid
pRB.TatC.2 was mutagenized with the EZ-TN5™ < KAN-
2 > Insertion Kit (Epicentre® Illumina®) and introduced
into Transformax™ EPI300™ electrocompetent cells. Chlo-
ramphenicol resistant (camR, specified by the vector
pCC1) and kanamycin resistant (kanR, specified by the
EZ-TN5 < KAN-2 > TN) colonies were selected and plas-
mids were analyzed by PCR using the pCC1-specific pri-
mer, P11 (5′-TACGCCAAGCTATTTAGGTGAGA-3′),
and primers specific for the kanR marker, P12 (5′-ACCT
ACAACAAAGCTCTCATCAACC-3′) and P13 (5′-GC
AATGTAACATCAGAGATTTTGAG-3′). This strategy
identified plasmid pRB.TatC:kan, in which the EZ-TN5 <
KAN-2 > TN was inserted near the middle of the tatC
ORF. The disrupted tatC gene was then amplified from
pRB.TatC:kan with the pCC1-specific primers P11 and
P14 (5′-TAATACGACTCACTATAGGG-3′) using Pla-
tinum® Pfx DNA Polymerase. This 2.3-kb PCR product
was purified and electroporated into M. catarrhalis strains
O12E and O35E to create the kanR isogenic mutant
strains O12E.TC and O35E.TC via homologous recombin-
ation. Allelic replacement was confirmed by PCR with the
tatC primers P1 and P2 using Platinum® Pfx DNA Poly-
merase. These primers yielded PCR products in the mu-
tant strains that were 1.2-kb larger than the amplicons
obtained in the wild-type (WT) isolates O35E and O12E
due to the presence of the EZ-TN5 < KAN-2 > TN in
tatC.
Table 1 Strains and plasmids used in this study
Strain Description Source
M. catarrhalis
O35E WT isolate from middle ear effusion (Dallas, TX) [94]
O35E.TA tatA isogenic mutant of strain O35E, kanR This study
O35E.TB tatB isogenic mutant of strain O35E, kanR This study
O35E.TC tatC isogenic mutant of strain O35E, kanR This study
O35E.Bro bro-2 isogenic mutant of strain O35E, kanR This study
O12E WT isolate from middle ear effusion (Dallas, TX) [28]
O12E.TC tatC isogenic mutant of strain O12E, kanR This study
McGHS1 WT isolate from patient with respiratory infection (Toledo, OH) [33]
TTA37 WT isolate from transtracheal aspirate (Johnson City, TN) [28]
V1171 WT isolate from nasopharynx of a healthy child (Chapel Hill, NC) [28]
H. influenzae
DB117 Host strain for cloning experiments with pWW115 [95,96]
E. coli
EPI300 Cloning strain Epicentre®
Illumina®
Plasmids
pCC1 Cloning vector, camR Epicentre®
Illumina®
pCC1.3 pCC1-based plasmid containing kanR marker, camRkanR [31]
pRB.TatA.5 Contains 886-nt insert specifying O35E tatA in pCC1, camR This study
pRB.TatB.1 Contains 858-nt insert specifying O35E tatB in pCC1, camR This study
pRB.TatC.2 Contains 1,018-nt insert specifying O12E tatC in pCC1, camR This study
pRB.TatC:kan pRB.TatC.2 in which a kanR marker disrupts the tatC ORF, camR kanR This study
pRB.Tat.1 Contains 2,083-nt insert specifying O35E tatABC locus in pCC1, camR This study
pRB.TatA:kan pRB.Tat.1 in which a kanR marker disrupts the tatA ORF, camR kanR This study
pRB.TatB:kan pRB.Tat.1 in which a kanR marker disrupts the tatB ORF, camR kanR This study
pRN.Bro11 Contains 994-nt insert specifying O35E bro-2 in pCC1, camR This study
pRB.Bro:kan pRN.Bro11 in which a kanR marker disrupts the bro-2 ORF, camR kanR This study
pTS.BroKK.Ec pRN.Bro11 in which 2 arginines in the signal sequence of the bro-2 gene
product were replaced with 2 lysines by site-directed mutagenesis, camR
This study
pWW115 M. catarrhalis-H. influenzae shuttle cloning vector, spcR [95]
pRB.TatA pWW115 into which the tatA insert of pRB.TatA.5 was subcloned, spcR This study
pRB.TatB pWW115 into which the tatB insert of pRB.TatB.1 was subcloned, spcR This study
pRB.TatC pWW115 into which the tatB insert of pRB.TatC.2 was subcloned, spcR This study
pRB.TAT pWW115 into which the tatABC locus of pRB.Tat.1 was subcloned, spcR This study
pTS.Bro pWW115 into which the bro-2 insert of pRN.Bro11 was subcloned, spcR This study
pTS.BroKK pWW115 into which the bro-2 insert of pTS.BroKK.Ec was subcloned, spcR This study
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M. catarrhalis O35E, the plasmid pRB.Tat.1 was first
mutagenized with the EZ-TN5™ In-Frame Linker In-
sertion Kit (Epicentre® Illumina®) and introduced into
Transformax™ EPI300™ electrocompetent cells. Plasmid
DNA was isolated from several camR (specified by the
vector pCC1) and kanR (specified by the EZ-TN5 <NotI/KAN-3 > TN) clones and sequenced to determine the
sites of insertion of the TN. This approach identified the
plasmids pRB.TatA:kan and pRB.TatB:kan, which contai-
ned the EZ-TN5 <Not I/KAN-3 > TN at nt 90 of the
tatA ORF and nt 285 of the tatB ORF, respectively.
These plasmids were then introduced into M. catarrha-
lis strain O35E by natural transformation as previously
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by PCR using primers specific for tatA (P3 and P4) and
tatB (P5 and P6), which produced DNA fragments that
were 1.2-kb larger in size in mutant strains when
compared to the WT strain O35E because of the in-
sertion of the EZ-TN5 <Not I/KAN-3 > TN in tatA
and tatB. This strategy yielded the mutant strains O35E.
TA and O35E.TB.
To construct a mutation in the bro-2 gene of M.
catarrhalis O35E, plasmid pRN.Bro11 was mutagenized
with the EZ-TN5™ In-Frame Linker Insertion Kit as de-
scribed above. Plasmids were isolated from kanR camR
colonies and sequenced to identify constructs containing
the EZ-TN5 <Not I/KAN-3 > TN near the middle of the
bro-2 ORF. This approach yielded the construct pRB.
Bro:kan, which was introduced in M. catarrhalis O35E
by natural transformation. Transformants were selected
for resistance to kanamycin and then tested for their
ability to grow on agar plates containing the β-lactam
antibiotic carbenicillin. KanR and carbenicillin sensitive
(cabS) strains were further analyzed by PCR using pri-
mers P9 and P10 to verify allelic exchange of the bro-2
gene. These primers produced a 1-kb DNA fragment in
the WT strain O35E and a 2.2-kb in the mutant O35E.
Bro, which is consistent with insertion of the 1.2-kb EZ-
TN5 <Not I/KAN-3 > TN in bro-2.
Site-directed mutagenesis of the M. catarrhalis bro-2 gene
The bro-2 ORF of M. catarrhalis O35E harbored by
plasmid pRN.Bro11 was mutated using the QuikChange
Lightning Site-Directed Mutagenesis Kit (Agilent Tech-
nologies) according to the manufacturer’s instructions.
The mutagenesis primers, P15 (5′- AAGGGGATAATG
ATGCAAAAGAAGCATTTTTTA-3′) and P16 (5′-GG
TTTTTTGTAAAAAATGCTTCTTTTGCAT CAT-3′),
were used to replace two arginine residues at position 4
and 5 of BRO-2 with two lysines, yielding plasmid pTS.
BroKK.Ec. This plasmid was sequenced to verify that
only the intended mutations were introduced in the bro-
2 ORF.
Complementation of mutants
The construction of plasmids to complement tat and
bro2 mutant strains was achieved as follows. Plasmid
DNA (pRB.TatA.5, pRB.TatB.1, pRB.TatC.2, pRB.Tat.1,
pRN.Bro11, pTS.BroKK.Ec) was digested with BamHI to
release the cloned M. catarrhalis genes from the vector
pCC1. Gene fragments were purified from agarose gel
slices using the High Pure PCR Product Purification Kit
(Roche Applied Science), ligated into the BamHI site of
the M. catarrhalis/Haemophilus influenza-compatible
shuttle vector pWW115 [95], and electroporated into H.
influenzae strain DB117. Spectinomycin resistant (spcR)
colonies were screened by PCR using the pWW115-specific primers P17 (5′-TACGCCCTTTTATACTGTA
G-3′) and P18 (5′-AACGACAGGAGCACGATCAT-3′),
which flank the BamHI cloning site, to identify clones
containing inserts of the appropriate size for the tat and
bro2 genes. This process produced plasmids pRB.TatA,
pRB.TatB, pRB.TatC, pRB.TAT, pTS.Bro, and pTS.BroKK.
The O35E.TA mutant was naturally transformed with
plasmids pWW115, pRB.TatA, and pRB.TatABC. The
plasmids pWW115, pRB.TatB, and pRB.TAT were intro-
duced in the O35E.TB mutant by natural transformation.
The tatC mutants O35E.TC and O12E.TC were naturally
transformed with the vector pWW115 and plasmid pRB.
TatC. The plasmids pWW115, pTS.Bro, and pTS.BroKK
were electroporated into the bro-2 mutant strain O35E.
Bro. The successful introduction of these plasmids into
the indicated strains was verified by PCR analysis of spcR
transformants with the pWW115-specific primers P17
and P18, and by restriction endonuclease analysis of plas-
mid DNA purified from each strain.
Growth rate experiments
Moraxella. catarrhalis strains were first cultured onto
agar plates supplemented with appropriate antibiotics.
These plate-grown bacteria were used to inoculate
500-mL sidearm flasks containing 20-mL of broth (with-
out antibiotics) to an optical density (OD) of 50 Klett
units. The cultures were then incubated with shaking
(225-rpm) at a temperature of 37°C for 7-hr. The OD
of each culture was determined every 60-min using a
Klett™ Colorimeter (Scienceware®). These experiments
were repeated on at least three separate occasions for
each strain. In some experiments, aliquots were taken
out of each culture after recording the optical density,
diluted, and spread onto agar plates to determine the
number of viable colony forming units (CFU).
Carbenicillin sensitivity assays
Moraxella catarrhalis strains were first cultured onto
agar plates supplemented with the appropriate antibi-
otics. These plate-grown bacteria were used to inoculate
sterile Klett tubes containing five-mL of broth (without
antibiotics) to an OD of 40 Klett units. Portions of these
suspensions (25 μL) were spotted onto agar medium
without antibiotics as well on plates supplemented with
carbenicillin, and incubated at 37°C for 48-hr to evaluate
growth. Each strain was tested in this manner a mini-
mum of three times.
Nitrocefin assays
Moraxella catarrhalis and H. influenzae strains were tes-
ted for their ability to cleave the chromogenic β-lactamase
substrate nitrocefin as previously described [98]. Bacterial
strains were first cultured onto agar plates supplemented
with appropriate antibiotics. These plate-grown cells were
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and aliquots (50 μL, ~107 CFU) were transferred to dupli-
cate wells of a 48-well tissue culture plate; control wells
were seeded with broth only. To each of these wells,
325 μL of a nitrocefin (Calbiochem®) solution (250 μg/mL
in phosphate buffer) was added and the absorbance at a
wavelength of 486 nm (A486) was immediately measured
using a μQuant™ Microplate Spectrophotometer (BioTek®)
and recorded as time “0”. The A486 of the samples was
then measured after a 30-min incubation at room tem-
perature. These experiments were repeated a minimum of
three times for each strain.
Sequence analyses and TAT prediction Programs
Sequencing results were analyzed and assembled using
Sequencher® 4.9 (Gene Codes Corporation). Sequence
analyses and comparisons were performed using the vari-
ous tools available through the ExPASy Proteomics Server
(http://au.expasy.org/) and NCBI (http://blast.ncbi.nlm.
nih.gov). To identify potential TAT substrates of M. ca-
tarrhalis, annotated nucleotide sequences from strain
ATCC43617 [81] were translated and analyzed with the
prediction algorithms available through the TatFind
1.4 (http://signalfind.org/tatfind.html) [82] and TatP
1.0 (http://www.cbs.dtu.dk/services/TatP/) [83] servers
using the default settings. The published genomic se-
quence of M. catarrhalis strain BBH18 [78] was ana-
lyzed in the same manner.
Statistical analyses
The GraphPad Prism Software was used for all statistical
analyses. Growth rate experiments and nitrocefin as-
says were analyzed by a two-way analysis of variants
(ANOVA), followed by the Bonferroni post-test of the
means of each time point. Asterisks indicate statisti-
cally significant differences where P < 0.05.
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